ACCURAY INC
For the period ended Jun 30, 2025. Filed Aug 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Aug 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| June 30, 2025 | June 30, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $57,416 | $68,570 |
| Restricted cash | 574 | 485 |
| Accounts receivable, net of allowance for credit losses of $369 and $2,251 as of June 30, 2025 and June 30, 2024, respectively (a) | 83,192 | 92,001 |
| Inventories | 141,020 | 138,324 |
| Prepaid expenses and other current assets (b) | 33,501 | 23,006 |
| Deferred cost of revenue | 1,762 | 850 |
| Total current assets | 317,465 | 323,236 |
| Noncurrent assets: | ||
| Property and equipment, net | 28,658 | 24,774 |
| Investment in joint venture | 4,612 | 9,826 |
| Operating lease right-of-use assets, net | 33,115 | 33,773 |
| Goodwill | 57,802 | 57,672 |
| Restricted cash | 4,144 | 1,337 |
| Other assets | 24,443 | 18,009 |
| Total assets | $470,239 | $468,627 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $34,033 | $50,020 |
| Accrued compensation | 14,573 | 17,128 |
| Operating lease liabilities | 7,375 | 6,218 |
| Other accrued liabilities | 29,361 | 28,508 |
| Customer advances | 12,197 | 13,988 |
| Deferred revenue | 82,306 | 71,649 |
| Short-term debt, net | 12,734 | 7,756 |
| Total current liabilities | 192,579 | 195,267 |
| Noncurrent liabilities: | ||
| Operating lease liabilities | 32,482 | 32,373 |
| Long-term other liabilities | 5,160 | 7,389 |
| Warrant liability | 8,497 | — |
| Deferred revenue | 26,566 | 24,114 |
| Long-term debt, net | 123,786 | 164,400 |
| Total liabilities | 389,070 | 423,543 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; authorized: 200,000,000 shares as of June 30, 2025 and June 30, 2024, respectively; issued and outstanding: 112,643,852 and 100,194,932 shares at June 30, 2025 and June 30, 2024, respectively | 113 | 100 |
| Additional paid-in-capital | 602,165 | 566,887 |
| Accumulated other comprehensive loss | (1,837) | (4,222) |
| Accumulated deficit | (519,272) | (517,681) |
| Total stockholders' equity | 81,169 | 45,084 |
| Total liabilities and stockholders’ equity | $470,239 | $468,627 |
(a)
Included accounts receivable from the joint venture, an equity method investment, of $28,452 and$25,339 at June 30, 2025, and June 30, 2024, respectively. See Note 11.
(b)
Included other receivable from the joint venture, an equity method investment, of$377 and$743 at June 30, 2025, and June 30, 2024, respectively.
The accompanying notes are an integral part of these consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.